AGMT
  • Die AGMT
    • Über uns
    • Vorstand
    • Team
    • Partner
    • Karriere
    • Kontakt
  • Studien
    • Hodgkin Lymphom
      • HD 21
      • AERN
      • BRESELIBET
    • Non-Hodgkin Lymphom
      • DSHNHL_NIVEAU
      • ORACLE
      • Pola-R-ICE
    • Multiples Myelom
      • MM-4
    • Pankreaskarzinom
      • DIsCOvER
    • COVID-19
      • INSERM_DisCoVeRy
  • Register
    • AIHA Registry
    • aMYELOIDr
    • ARIADNE NIS
    • CLL-Register
    • COVID-19 Register
    • LungCA Register
    • MBC Register
    • NGS Register
    • PTCL Register
  • Veranstaltungen
    • AGMT Jahresmeeting
    • Breast Cancer Talk
    • GI Cancer Summit
  • Publikationen
  • News
    • News Übersicht
    • Newsletter
    • News Archiv
  • Kontakt
  • AAA
  • Login
  • de
    Languages
    • en English
    • de Deutsch

Kolorektalkarzinom

  • SAKK 41/14 Active-2
SAKK 41/14 Active-2

SAKK 41/14 Active-2

Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy. A multicenter open label randomized controlled trial.

Synopsis

Short title: SAKK 41/14 Active-2

Title: Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy. A multicenter open label randomized controlled trial.

Status: closed

Start: June 2016 (in Austria)

Coordinating Investigator: Univ. Prof. Dr. Josef Thaler (in Austria)

EudraCT Number: 2015-003733-10

ClinicalTrialsID: na

Number of patients: 300 (international)

Sponsor: SAKK (Swiss Group for Clinical Cancer Research), AGMT Sponsor representative in Austria

Design

All patients will undergo standard systemic therapy for metastatic colorectal cancer. Patients in the care-as-usual group are not actively encouraged to change their physical activity level e.g. to start a fitness program during chemotherapy.

The physical exercise ACTIVE-program describes a 12-week exercise program consisting of a combination of a bi-weekly aerobic exercise (cycle ergometer) supervised by a physical therapist and a self-paced increase in physical activity during daily life using a pedometer with a daily step goal as a motivational tool. The program will be individually tailored to each patient based on the training protocol and is aimed at increasing physical activity levels and cardiorespiratory fitness.

Primary objective:

To assess whether a structured physical activity program (PA) during palliative chemotherapy improves progression-free survival (PFS) and/or patient-reported outcomes (ESAS-r) in patients with metastatic colorectal cancer.

Primary endpoints:

The co-primary endpoints are PFS and patient-reported symptoms as measured by the ESAS-r (Edmonton Symptom Assessment System revised).

Secondary endpoints:
  • Efficacy
  • Chemotherapy-related endpoints and toxicities
  • Patient reported outcomes
  • Exercise endpoints

Inclusion/Exclusion criteria

Inclusion criteria (selected):
  • Written informed consent according to ICH/GCP regulations before randomization
  • Patients with histologically or cytologically confirmed colorectal carcinoma (CRC) who start palliative first-line systemic therapy for inoperable or metastatic disease.
    Note: Patients can be included before the start or within the first three weeks of first-line systemic treatment
  • Patients with histologically or cytologically confirmed colorectal carcinoma (CRC), who start first-line “conversion”-therapy for borderline resectable metastatic disease and will be reassessed for metastasectomy after 3-4 months of systemic treatment.
    Note: Patients can be included before the start or within the first three weeks of first-line systemic treatment
  • Patients who are diagnosed with metastatic disease and were initially treated with surgery and/or radiochemotherapy to the primary tumor are eligible (except if all disease sites/metastases have been removed)
  • Patients who have been curatively treated with histologically or cytologically confirmed nonmetastatic CRC previously and now relapse with metastatic disease are also eligible, irrespective of previous radiochemotherapy and/or adjuvant chemotherapy
  • Patients must have measurable disease on CT scan or MRI to be performed within 6 weeks before randomization (measurability criteria according to RECIST 1.1, non-nodal lesions ≥10 mm, lymph nodes ≥15mm) OR evaluable disease i.e. patient with nonmeasurable metastases but elevated serum tumor-marker (CEA at least >2xULN).
  • Command of written and spoken language allowing for informed consent and for filling in trial questionnaires
  • Baseline patient-reported outcomes (PROs) have been completed
  • WHO performance status 0-2
  • Age ≥18 years
Exclusion criteria (selected):
  • Pre-existing severe medical conditions precluding participation in a physical activity program as determined by the local investigator
  • Inability to ride a cycle ergometer e.g. for musculoskeletal reasons
  • Patients in whom all CRC metastases have been removed surgically

Studien
  • Studien
    • Hodgkin Lymphom
      • HD21
      • AERN
      • BRESELIBET
    • Non-Hodgkin Lymphom
      • DSHNHL_NIVEAU
      • ORACLE
      • Pola-R-ICE
    • Multiples Myelom
      • MM-4
    • Pankreaskarzinom
      • DIsCOvER
    • COVID-19
      • INSERM_DisCoVeRy
Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Firmensitz und Rechnungsadresse: Gentzgasse 60/21, 1180 Wien
Zweigstelle & Zustelladresse: Wolfsgartenweg 31, 5020 Salzburg
Firmenbuchnummer: FN 289548 g
UID-Nummer: ATU63467108
+43 662 640 44 12
+ 43 664 142 25 04
+43 662 640 44 14
office@agmt.at
Copyright © AGMT gemeinnützige GmbH
  • Impressum
  • Datenschutzerklärung
  • LinkedIn AGMT